MRNA
NASD Moderna, Inc.$198.66 ↑ +1.38 (+0.70%) Trading Up from the previous close of $197.28, $10.24 below the day’s high of $208.90
- YTD change
- +573.65%
- vs 20-day SMA
- +25.21%
- vs 200-day SMA
- +205.16%
Price ranges
Price & Performance
+149.05 (+309.04%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 60.1% away from all-time highs of $497.49
- MRNA is up 574% since the beginning of the year
- MRNA is up 684% over the past 12 months
- MRNA is up 44% over the past 1 month
- 9% of all MRNA investors are betting against MRNA
MRNA reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +678.8%.
- Previous minute
- +$0.01
- Last hour
- +$2.65
- Last 5 days
- +14.87%
- vs 8-day SMA
- +10.31%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
